5. Peripartum Cardiomyopathy

Quick Recap

Obstetrics System, Protocol 5/6. Builds on the Acute Heart Failure protocol (Cardiovascular System) with pregnancy-specific medication safety and delivery-coordination nuance.

1. Definition & Epidemiology

Peripartum cardiomyopathy (PPCM) = new-onset heart failure WITHOUT a known cause, occurring in the peripartum window. Incidence approximately 1 in 2,000 patients — common enough to be a genuinely frequent indication for obstetric critical care, not a rare curiosity.

Diagnosis: echocardiogram with EF <=45%, WITH or WITHOUT ventricular dilation.

Timing: most commonly within 1 MONTH of delivery, but can occur PRIOR to delivery or up to 1 YEAR postpartum — a broad window that requires maintaining suspicion well beyond the immediate delivery period.

Presentation: standard heart failure signs/symptoms — dyspnea, fatigue, edema, tachypnea. Given these symptoms overlap substantially with NORMAL late pregnancy/early postpartum physiology (baseline dyspnea, edema, fatigue are common in uncomplicated pregnancy), genuine diagnostic delay risk exists — maintain a lower threshold for echocardiography in a peripartum patient with these symptoms, especially if disproportionate to expected physiologic changes.

2. Pregnancy-Specific Pharmacotherapy — Timing-Dependent Restrictions

Standard acute heart failure management principles apply (see Acute Heart Failure protocol, Cardiovascular System, for the Forrester wet/dry-warm/cold framework and general decongestion strategy) — but medication SAFETY differs substantially based on whether the patient is PRE- or POST-delivery.

Safe throughout pregnancy AND postpartum:

• Loop diuretics: first-line for symptomatic pulmonary/peripheral congestion relief
• Beta-blockers (sustained-release metoprolol succinate, carvedilol, bisoprolol): shown to REDUCE MORTALITY in HFrEF generally — first-line therapy for ALL stable patients unless contraindicated, safe across the pregnancy/postpartum spectrum
• Digoxin: safe in pregnancy with the SAME monitoring intensity as nonpregnant patients
• Hydralazine and nitrates: the VASODILATORS OF CHOICE specifically FOR PREGNANT women (given ACEI/ARB contraindication before delivery, Section below)

CONTRAINDICATED before delivery, permitted ONLY postpartum:

• ACE inhibitors and angiotensin receptor blockers (ARBs): teratogenic — contraindicated antepartum; may be ADDED once the patient has delivered
• This pre/post-delivery restriction is THE central pharmacotherapy decision point in PPCM management — the same guideline-directed heart failure therapy that would be first-line in a nonpregnant patient must be deliberately withheld until after delivery

Anticoagulation:

• Enoxaparin commonly added for severely reduced LVEF (<30%) given intraventricular thrombus risk from the markedly hypokinetic, often dilated ventricle
• Anticoagulation to prevent systemic thromboembolism is recommended in ALL PPCM patients until EITHER cardiomyopathy resolution OR 3 MONTHS POSTPARTUM, whichever occurs FIRST — a specific, dual-endpoint duration rule
• Warfarin is generally AVOIDED during pregnancy for this indication — crosses the placenta, associated with fetal nasal, ophthalmologic, and CNS abnormalities. Heparins (unfractionated or LMWH) are the mainstay throughout the ENTIRE pregnancy period; oral anticoagulants (warfarin) are started ONLY after delivery if anticoagulation is still needed at that point

Experimental therapy:

• Bromocriptine (a prolactin-inhibiting dopamine agonist) has been investigated as a PPCM-specific mechanistic treatment, targeting a proposed pathophysiologic pathway involving cleaved prolactin fragments — usage should currently be LIMITED to IRB-approved research protocols, not routine clinical practice, given the evidence base remains investigational

Explicitly AVOIDED medications (general heart failure principles, reinforced in PPCM): ACEI/ARB before delivery (per above), NSAIDs, many antiarrhythmic drugs, non-dihydropyridine calcium channel blockers.

3. Delivery Coordination — A Genuine Multidisciplinary Challenge

Delivery in the setting of ACUTE heart failure presents a significant management challenge — the hemodynamic stress of labor/delivery can worsen an already-compromised cardiovascular system, while ongoing severe heart failure itself threatens both mother and fetus.

Coordination requires a full multidisciplinary team: obstetrics, cardiology, maternal-fetal medicine, anesthesiology, AND neonatology — more services than almost any other single obstetric emergency in this system, reflecting the genuine complexity of balancing acute cardiac stabilization against delivery timing.

Attempts to STABILIZE the patient to AVOID delivery during the acute decompensation period are reasonable — unlike some obstetric emergencies (eclampsia, HELLP) where delivery is the definitive treatment and should not be delayed, PPCM management may specifically favor stabilizing first if feasible, since delivery itself adds hemodynamic stress rather than resolving the underlying cardiomyopathy.

Invasive hemodynamic monitoring may be beneficial to assess for rapid fluid shifts during this period, given the volume-management complexity of concurrent heart failure and pregnancy physiology.

If LVEF is particularly poor, involve the ECMO team proactively in case urgent postpartum cannulation is needed — anticipate this need rather than reacting to acute decompensation without a plan already in place.

4. Prognosis

Highly variable: ranges from COMPLETE RECOVERY to PERMANENT dysfunction, or even deterioration requiring HEART TRANSPLANTATION. This wide prognostic range should inform family counseling — avoid both false reassurance and excessive pessimism, since outcome is genuinely unpredictable at presentation and requires ongoing reassessment of trajectory.

5. Investigations

Echocardiogram (diagnostic, EF <=45% +/- dilation), BNP/NT-proBNP (with the caveat that these markers can be elevated by many other conditions — see Acute Heart Failure protocol — and should be interpreted in clinical context, not diagnostic in isolation), troponin (mild elevation common in decompensated HF generally, should not be mistaken for ACS), renal/hepatic function (congestion-related derangement), electrolytes, ECG.

6. Organ Support

Diuresis and beta-blockade as first-line (per Section 2); vasodilators (hydralazine/nitrates) for afterload reduction pre-delivery; ACEI/ARB addition post-delivery; anticoagulation per the LVEF<30%-or-general-PPCM-risk indication; invasive hemodynamic monitoring during the peridelivery period; ECMO as an anticipated rescue option for severe LV dysfunction; mechanical circulatory support per the general Cardiogenic Shock protocol (Cardiovascular System) if PPCM progresses to frank cardiogenic shock (note PPCM is explicitly listed as a recognized cardiogenic shock etiology in that protocol's LV failure category).

7. Consultation Matrix

8. Monitoring Framework

Serial echo (EF trend, recovery vs progression), invasive hemodynamic monitoring during the peridelivery period if used, fluid balance (diuresis response), renal/hepatic function trend, anticoagulation monitoring, fetal monitoring until delivery.

9. Complications

Progression to cardiogenic shock (see dedicated protocol, Cardiovascular System), intraventricular thrombus/systemic thromboembolism (especially EF<30% without anticoagulation), arrhythmia, need for mechanical circulatory support or transplantation, maternal death, fetal complications from either the underlying maternal instability or iatrogenic preterm delivery. Prevention: appropriate pregnancy-timing-adjusted pharmacotherapy, anticoagulation per the LVEF/duration criteria, proactive ECMO team involvement for severe cases, multidisciplinary delivery timing coordination favoring stabilization before delivery where feasible. Rescue: full Cardiogenic Shock protocol escalation (inotropes, MCS) if progression occurs, ECMO for refractory cases, resuscitative cesarean delivery per the Obstetric Hemorrhage protocol principles if maternal cardiac arrest occurs.

10. Escalation & De-escalation

Escalate: progression to cardiogenic shock despite diuresis/beta-blockade -> full Cardiogenic Shock protocol (inotropes, MCS), ECMO team activation.

De-escalate: EF improving, decongestion achieved, hemodynamically stable -> add ACEI/ARB if postpartum, continue anticoagulation per the LVEF/duration criteria, transition to standard cardiology follow-up with serial echo surveillance for recovery trajectory.

11. ICU Discharge Criteria

Hemodynamically stable, decongested, guideline-directed therapy established appropriate to pregnancy/postpartum status, anticoagulation plan in place if indicated, delivery completed (or a defined stabilization-before-delivery plan with multidisciplinary follow-up if pre-delivery), cardiology follow-up arranged for EF trend surveillance.

12. Documentation & Medicolegal Checklist

13. Key Guidelines

Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133(14):1397-1409.

14. Controversies

Bromocriptine's role remains investigational, restricted to IRB-approved protocols rather than standard practice, despite mechanistic appeal — the evidence base has not yet matured to support routine clinical use. The decision to stabilize-and-delay delivery vs proceed with expedited delivery in acute PPCM decompensation involves genuine, individualized maternal-fetal risk-benefit judgment without a single algorithmic answer, reflecting real clinical complexity acknowledged in the primary references.

15. References

1. Care of the Pregnant Patient in the ICU (Peripartum Cardiomyopathy section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 71).
2. Bhatia PK, Biyani G, Mohammed S, Sethi P, Bihani P. Acute Respiratory Failure and Mechanical Ventilation in Pregnant Patient (PPCM treatment table). ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 19).
3. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133(14):1397-1409.
4. Cardiogenic Shock chapter (PPCM as a recognized LV failure etiology). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 4).

See also: Acute Heart Failure and Cardiogenic Shock (Cardiovascular System) for the general heart failure/shock management framework this protocol adapts for pregnancy; Obstetric Hemorrhage (Obstetrics System) for the resuscitative cesarean delivery principle relevant if maternal cardiac arrest occurs.